Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8311 to 8325 of 8944 results

  1. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued Reference number: GID-TAG496

    Technology appraisal guidance
    Discontinued

  2. Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]

    In development Reference number: GID-TAG499 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued Reference number: GID-TAG507

    Technology appraisal guidance
    Discontinued

  4. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued Reference number: GID-TAG511

    Technology appraisal guidance
    Discontinued

  5. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued Reference number: GID-TAG526

    Technology appraisal guidance
    Discontinued

  6. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development Reference number: GID-TA10858 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Spesolimab for preventing generalised pustular psoriasis flares [ID6216]

    In development Reference number: GID-TA11189 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued Reference number: GID-TA11124

    Technology appraisal guidance
    Discontinued

  9. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development Reference number: GID-TA11455 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued Reference number: GID-MT557

    Medical technologies guidance
    Discontinued

  11. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

    Medical technologies guidance
    Discontinued

  12. The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

    Discontinued Reference number: GID-MT517

    Medical technologies guidance
    Discontinued

  13. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Discontinued Reference number: GID-TA11338

    Technology appraisal guidance
    Discontinued

  14. Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

    In development Reference number: GID-TA11528 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]

    In development Reference number: GID-TA11654 Expected publication date: TBC

    Technology appraisal guidance
    In development